NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Magnolia Medical Technologies

Magnolia Medical Technologies

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://magnolia-medical.com/

Last Round

Growth Equity

Feb 16, 2022

Total Funding Raised

$116M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Magnolia Medical Technologies is a healthcare company that develops blood-collection systems designed to eliminate sepsis misdiagnosis by preventing false-positive blood culture results through a sterile, closed collection process.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Healthcare Analytics

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

blood culture contaminationsepsis preventionblood collection devicediagnostic stewardshipblood culture accuracysepsis misdiagnosisclinical data analyticshospital infection controlelectronic health record integrationEHR integrationlaboratory information systemLISfalse positive reductioninfection preventionmedical device commercialization

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Magnolia Medical Technologies Comps

Public and private peers based on sector, stage, and business model.

Magnolia Medical Technologies comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Magnolia Medical Technologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Growth EquityFeb 16, 2022
DebtMay 27, 2020
Series CJan 30, 2019
Series B ExtensionApr 4, 2017
Series BJul 13, 2016
Series A
Nov 1, 2014

Key People

Founding team and executive leadership

Jason Richey

President Chief Executive Officer

Executive Team

Joe Bishop

Chief Operating Officer

Executive Team

Magnolia Medical Technologies Investors

Notable investors and investment history

Magnolia Medical Technologies investors
InvestorRounds
Janus Henderson GroupGrowth Equity
Evidity Health CapitalGrowth Equity, Series C
SightLine PartnersGrowth Equity, Series C
Horizon Technology Finance CorporationDebt
SectoralGrowth Equity
RTW InvestmentsGrowth Equity, Series C
Band of AngelsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Company holds over 70 issued patents with 50+ applications pending.

  • Apr 1, 2026

    Steripath device receives FDA-cleared indication for reducing blood culture contamination.

Magnolia Medical Technologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Magnolia Medical Technologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Magnolia Medical Technologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range80
Year Founded2006
Last FundingFeb 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.